Kalaris Therapeutics Inc is a clinical-stage biopharmaceutical company focused on developing and commercializing therapeutics for prevalent retinal diseases. The company is developing TH103, a novel, clinical-stage anti-vascular endothelial growth factor VEGF drug, engineered to potentially provide longer-lasting and increased anti-VEGF activity in patients with exudative and neovascular retinal diseases. TH103 is a fully humanized recombinant fusion protein, functioning as a decoy receptor (a VEGF trap), leveraging salient molecular properties of the human body's native, highest affinity VEGF receptor 1.
Last trade$1.38
Day change-$0.08 (-5.48%)
Day range$1.37 – $1.48
Volume175,445
Market cap$35M
OpenXNAS
Fundamentals
Key company ratios and reported financial statements.
Source: Massive.com
Key ratios
Valuation
Market capitalization
$34.76M
Price / earnings
—
Price / book
0.73×
Price / sales
—
EV / sales
—
EV / EBITDA
0.27×
Profitability
Earnings per share
-$1.82
Return on assets
-48.76%
Return on equity
-91.55%
Dividend yield
0%
Liquidity and leverage
Debt / equity
0×
Current ratio
10×
Quick ratio
10×
Cash ratio
5.57×
Cash flow
Price / cash flow
—
Price / free cash flow
—
Free cash flow
-$40.26M
Ratios use trailing-twelve-month financials and market data as of
Nov 16, 2026.
Financial statements
Income and cash flow amounts are for the period; balance sheets are point-in-time
snapshots. Amounts are shown in USD. Latest 8 quarterly or 5 annual periods are
displayed when available.
Income statement for KLRS, quarterly periods
Line item
Q3 FY2026 Sep 30, 2026
Q2 FY2026 Jun 30, 2026
Q1 FY2026 Mar 31, 2026
Q4 FY2025 Dec 31, 2025
Q3 FY2025 Sep 30, 2025
Q2 FY2025 Jun 30, 2025
Q1 FY2025 Mar 31, 2025
Revenue
$0
$0
$0
$0
$0
$0
$0
Cost of revenue
$0
$0
$0
$0
$0
$0
$0
Gross profit
$0
$0
$0
$0
$0
$0
$0
Selling, general and administrative
$3.47M
$3.37M
$4.26M
$3.64M
$3.62M
$3.82M
$4.32M
Research and development
$8.34M
$9.02M
$7.57M
$7.16M
$9.13M
$8.44M
$6.03M
Total operating expenses
$11.81M
$12.39M
$11.83M
$10.8M
$12.74M
$12.26M
$10.35M
Operating income
-$11.81M
-$12.39M
-$11.83M
-$10.8M
-$12.74M
-$12.26M
-$10.35M
Interest expense
$0
$0
$0
$0
$0
$0
-$1.44M
Income before taxes
-$11.03M
-$11.52M
-$10.86M
-$10M
-$11.89M
-$11.35M
-$10.2M
Income taxes
$0
$0
$0
$0
$0
$0
$0
Net income
-$11.03M
-$11.52M
-$10.86M
-$10M
-$11.89M
-$11.35M
-$10.2M
Net income attributable to common shareholders
-$11.03M
-$11.52M
-$10.86M
-$10M
-$11.89M
-$11.35M
-$10.2M
EBITDA
-$11.8M
-$12.38M
-$11.82M
-$10.79M
-$12.74M
-$12.26M
-$10.35M
Basic earnings per share
-$0.46
-$0.48
-$0.46
-$0.51
-$0.64
-$0.61
-$2.52
Diluted earnings per share
-$0.46
-$0.48
-$0.46
-$0.51
-$0.64
-$0.61
-$2.52
Recent news
Company coverage with links to the original publishers.
Kalaris Therapeutics (Nasdaq: KLRS), a clinical-stage biopharmaceutical company, announced that management will participate in a Fireside Chat at the Morgan Stanley 24th Annual Global Healthcare Conference on September 15, 2026. The company is developing TH103, a dual-action anti-VEGF therapeutic, currently in Phase 1b/2 trials for neovascular Age-related Macular Degeneration (nAMD), with preliminary data expected in the first half of 2027.
Abbott Cooper PLLC is investigating potential fiduciary duty breaches by the board of directors of Stablecoin Development Corporation (formerly NovaBay Pharmaceuticals, Inc.). The investigation targets stockholders who continuously held shares since prior to August 19, 2025. Similar investigations are also underway for Kalaris Therapeutics (formerly AlloVir) and Abundia Global Impact Group (formerly Houston American Energy Corp.).
Kalaris Therapeutics announced positive Phase 1a data for TH103, its investigational treatment for neovascular AMD. The expanded trial of 17 treatment-naive patients showed improvements in vision and retinal anatomy, with 29% requiring no additional anti-VEGF treatment during six-month follow-up. TH103 demonstrated 27-53 fold lower plasma levels compared to leading anti-VEGF agents while maintaining efficacy. The company is actively enrolling patients in Phase 1b/2 trials with preliminary data expected in H1 2027.
Kalaris Therapeutics announced it will present Phase 1a clinical data for TH103, a novel dual-targeting VEGF/HSPG biologic, at the American Society of Retina Specialists 2026 Annual Meeting on July 17, 2026. The company's Phase 1b/2 multiple ascending dose study for neovascular age-related macular degeneration is actively enrolling patients, with initial data expected in the first half of 2027.
Kalaris Therapeutics secured a $50 million private placement with institutional investors to advance clinical development of TH103 for neovascular AMD, with funds expected to support operations through Q3 2027.
Dividends
Declared distributions and recorded event dates. Forecasts are not
shown.
Updated daily
No declared upcoming dividend found.
No prior dividend records found.
Stock splits
Historical share-structure events and their execution dates.